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Exploring the biological role 
of postzygotic and germinal de 
novo mutations in ASD
A. Alonso‑Gonzalez1,2, M. Calaza1,2, J. Amigo3, J. González‑Peñas4, R. Martínez‑Regueiro1,2, 
M. Fernández‑Prieto1,2, M. Parellada4, C. Arango4, Cristina Rodriguez‑Fontenla2,5* & 
A. Carracedo1,2,3,5
De novo mutations (DNMs), including germinal and postzygotic mutations (PZMs), are a strong source 
of causality for Autism Spectrum Disorder (ASD). However, the biological processes involved behind 
them remain unexplored. Our aim was to detect DNMs (germinal and PZMs) in a Spanish ASD cohort 
(360 trios) and to explore their role across different biological hierarchies (gene, biological pathway, 
cell and brain areas) using bioinformatic approaches. For the majority of the analysis, a combined 
ASD cohort (N = 2171 trios) was created using previously published data by the Autism Sequencing 
Consortium (ASC). New plausible candidate genes for ASD such as FMR1 and NFIA were found. In 
addition, genes harboring PZMs were significantly enriched for miR‑137 targets in comparison with 
germinal DNMs that were enriched in GO terms related to synaptic transmission. The expression 
pattern of genes with PZMs was restricted to early mid‑fetal cortex. In contrast, the analysis of genes 
with germinal DNMs revealed a spatio‑temporal window from early to mid‑fetal development stages, 
with expression in the amygdala, cerebellum, cortex and striatum. These results provide evidence of 
the pathogenic role of PZMs and suggest the existence of distinct mechanisms between PZMs and 
germinal DNMs that are influencing ASD risk.
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Background
Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder (NDD) characterized by deficits in com-
munication and social interaction together with restricted interests and repetitive  behaviors1. ASD prevalence 
among children in the United States stands at around 1.5% and has rapidly risen in recent years. In addition to the 
core symptoms of ASD, other conditions such as epilepsy or intellectual disability are often present. Comorbidity 
is a characteristic of ASD that can appear at any time during child’s development. Since many ASD cases with 
comorbidity have a clear genetic background and early detection is key for intervention, the genetic diagnosis 
in this type of cases is a  challenge2.
Twin and family studies have estimated ASD heritability to be about 80% and subsequent genetic studies 
have demonstrated that the largest part of this heritability (50%) is explained by common  variation3,4. However, 
de novo rare genetic variation (minor allele frequency < 0.1%), including small insertions and deletions (indels), 
copy number variants and single nucleotide variants confers higher individual  risk5–7. Germinal de novo muta-
tions (DNMs) occur within germ cells and they are transmitted to the offspring when the zygote is formed after 
fertilization. Thus, every single cell line of the resulting embryo will carry an identical genetic load. Another 
type of DNMs, postzygotic mutations (PZMs), arise during zygote mitosis, leading to a mosaic of genetically 
different cell  lines8. The frequency of mutagenesis and the generation of PZMs is increased prior to gastrulation 
and  neurogenesis9.
PZMs involved in ASD pathogenesis are usually detectable through deep sequencing of brain tissues. How-
ever, this technique often entails a huge challenge due to the inability to obtain ASD brain  samples10. In contrast, 
next generation sequencing technologies can be used to detect mosaic mutations in peripheral blood of affected 
individuals by increasing the depth of  coverage11. Thus, it is possible to obtain enough sequencing reads con-
taining the reference and the alternate allele to accurately calculate the alternate allele frequency (AAF)12. In 
PZMs, the AAF value shifts from the expected 50/50 ratio for heterozygous germinal mutations. High coverage 
whole exome sequencing (WES) (depth > 200×) provides enough sensitivity to detect PZMs presenting AAF 
values as lower as 15%13,14. It is worthy to note that most WES studies have missed PZMs due to the commonly 
employed pipelines. The development of new variant calling pipelines is therefore needed and some efforts have 
been done in this  regard15–18.
It has been estimated that 7.5% of DNMs are PZMs that contribute about 4% to the overall architecture of 
ASD. PZMs have been identified in high-confidence ASD risk genes. Other novel ASD candidate genes such as 
KLF16 and MSANTD2, were discovered after studying the contribution of PZMs to ASD risk in large collections 
of ASD  probands18. This points to the fact that some genes carry a larger number of mutations in a mosaic state 
than other genes. In addition, a detailed analysis of non-synonymous PZMs has revealed that these variants are 
mainly found in brain-expressed genes and in Loss-of-function (LoF)-constrained exons. The spatio-temporal 
analysis across different developmental stages also points to brain areas, like the amygdala, that have not been 
previously highlighted by other WES studies in which PZMs were not  considered16,18.
The relevance of PZMs in the pathogenesis of ASD and the biological processes in which genes carrying PZMs 
are involved, remain largely unexplored. Moreover, the contribution of PZMs to the phenotypic presentation is 
another subject that should be studied in more detail using large-scale studies. Hence, it is suspected that ASD 
probands carrying mosaic mutations might be less affected than probands carrying germinal mutations as it 
happens in other NDDs such as Proteus syndrome or several brain  malformations19,20. Therefore, the main aim 
of this study was to accurately detect DNMs (germinal and PZMs) in a cohort of Spanish trios with ASD (360). 
The novel DNMs detected in the Spanish cohort were combined with a list of DNMs previously published by the 
Autism Sequencing Consortium (ASC)18 in a cohort of 5947 families (4032 ASD trios and 1918 quads) in order 
to study if different ASD risk genes tend to accumulate one or another type of mutations using different bioinfor-
matic approaches. In addition, the different biological implications of germinal and PZMs in ASD were explored 
through enrichment analysis approaches, which have not been applied before to this class of mutations across 
different hierarchical levels (gene, GO terms, neuronal cell types and brain areas) (Additional file 4. Fig. S1).
Methods
Subjects. DNA was extracted from peripheral blood of the Spanish ASD samples (360 trios; unaffected 
parents and affected proband) using the GentraPuregene blood kit (Qiagen Inc., Valencia, CA, USA). Subjects 
from Santiago (N = 136) were recruited from Complexo Hospitalario Universitario de Santiago de Compostela 
and Galician ASD organizations. Subjects from Madrid (N = 224) were recruited as part of AMITEA program 
at the Child and Adolescent Department of Psychiatry, Hospital General Universitario Gregorio Marañón. 
Only individuals 3 years old or older were included. All participants had a clinical diagnosis of ASD made by 
trained pediatric neurologists or psychiatrists based on the Diagnostic and Statistical Manual of Mental Disor-
ders, Fourth Edition Text Revision and Fifth Edition (DSM-IV-TR and DSM-5) criteria. The Autism Diagnostic 
Observation Schedule (ADOS) and the Autism Diagnostic Interview-Revised (ADI-R) were also administered 
when necessary. Informed consent signed by each participating subject or legal guardian and approval from the 
corresponding Research Ethics Committee were obtained before the start of the study. All participants, parents 
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or legal representatives provided written informed consent at enrollment and the study was conducted according 
to the declaration of Helsinki.
Sample quality control and DNMs detection. Data processing and annotation. WES of DNA ex-
tracted from the Spanish 360 trios was performed by the ASC (https ://genom e.emory .edu/ASC/)21. One multi-
sample VCF with the raw results was retrieved from the ASC. Individual files containing coding variants per 
individual were obtained using bcftools and were annotated using SnpEff (Genomic variant annotations and 
functional effect prediction toolbox) version 4.3 T (http://snpeff .sourc eforg e.net/).
Sample specific quality control. To check family relationships in the Spanish cohort (360 trios), information of 
Mendelian error counts was obtained using the "–mendel” option available in VCFtools (http://vcfto ols.sourc 
eforg e.net/). Samples whose Mendelian errors significantly deviated from the expectation were not considered 
for subsequent analysis.
To identify discrepancy between nominal designed and genetically determined sex the “–sexcheck” option 
in PLINK was used to infer correct sex from genotypes on chromosome X and Y.
Finally, to identify outlier samples in the Spanish cohort (360 trios), the “pseq i-stats” command in PLINK 
was used. Samples in which any of the following parameters: count of alternate, minor, heterozygous genotypes, 
number of called variants or genotyping rate deviated more than 4 SD from the mean were eliminated. Therefore, 
the whole trio was dropped if any member was considered an outlier.
The samples of the Spanish cohort (360 trios) that passed all the quality controls mentioned above were the 
same as those included in Satterstrom et al.21.
DNMs detection. To detect DNMs in the Spanish cohort (360 trios), defined as those mutations that are strictly 
present in probands and not in parents, the filtering options published by Lim et al. were  employed18. In this 
study, variants classified as PZMs were resequenced by three different sequencing technologies reaching a high 
validation rate (87–97%).
Briefly, we define DNMs as those variants whose genotypes were 1/0 or 1/1 in probands and 0/0 in parents. 
Then, variants with GQ ≥ 20 and alternate read depth ≥ 7 were considered. Variants that present two or more 
alleles in the ExAC database (http://exac.broad insti tute.org/) were filtered out. Inframe indels were also filtered 
and only biallelic DNMs were considered. In addition, we filtered out variants that were less than 20 base pairs 
apart from each other to reduce false positives, and variants whose RVIS (Residual Variation Intolerance Score) 
retrieved from ExAC was higher than 75% were also filtered out. RVIS is designed to rank genes in terms of 
whether they have more or less common functional genetic variation relative to the genome-wide expectation 
given the amount of apparently neutral variation the gene has. Intolerant genes are more likely to be better candi-
dates in NDDs. Thus, RVIS values represented as percentiles reflect the relative rank of the genes, with those genes 
above 75th percentile being the most tolerant and therefore less likely to harbor mutations with a role in ASD.
SnpEff was employed to classify exonic variants according to the definition of their predictive impact: high, 
moderate and low impact on the canonical transcript. Low impact variants included silent mutations, moderate 
impact variants included missense mutations and high impact included splicing and nonsense mutations. Only 
base substitutions were considered so frameshift variants were filtered out.
Two different in silico prediction tools (CADD and SIFT) were used to classify missense mutations. Probably 
damaging mutations were those predicted as damaging by SIFT and variants with CADD score > 20 (Additional 
file 1; Table S1).
Finally, DNMs were classified as germinal or PZMs based on the AAF (number of alternate reads/(total 
number of reference + alternate reads)). DNMs with an AAF ≥ 0.40 were classified as germinal and DNMs with 
an AAF < 0.40 were classified as  PZMs18.
90 samples from the Spanish cohort (360 trios) were already analyzed by Lim et al.18 and they were used 
as positive controls to check if the detection of PZMs in the Spanish cohort was accurately made. Therefore, it 
was proved that most of DNMs were accurately detected and classified as germinal or PZMs (Additional file 1; 
Tables S1, S2).
For the majority of the analysis, we used a dataset called “combined cohort” (N = 2171) that includes the non-
synonymous DNMs detected in the 360 Spanish trios plus the non-synonymous DNMs identified in individuals 
with ASD sequenced by the ASC and published previously. Duplicated variants in both cohorts were eliminated 
(Supplementary Table 3 of Lim et al.)18 (Additional file 1; Table S1 and S3). For some analysis, we also defined a 
control cohort of healthy siblings published by the ASC (same sequencing depth and variant calling procedures 
than the probands of the Spanish cohort) (N = 288)1,18 (Additional file 1; Table S4).
Transmission and de novo association test (TADA‑denovo). TADA-Denovo (http://www.compg 
en.pitt.edu/TADA/TADA_guide .html#tada-analy sis-of-de-novo-data-tada-denov o) was run to discover and to 
prioritize ASD risk genes for both DNMs (germinal and PZMs) in the Spanish cohort (N = 360) (Additional 
file 1; Table S1) and in the combined dataset (N = 2171) (Additional file 1; Table S3). TADA takes into account 
the mutational burden of the genes as well as the multiple mutational  classes22. TADA was independently run in 
two different gene-sets for the Spanish cohort (genes harboring PZMs (PZMs genes) in the Spanish cohort = 105; 
genes harboring germinal DNMs (Germinal genes) in the Spanish cohort = 181) and for the combined cohort 
(PZMs genes in the combined cohort = 362; germinal genes in the combined cohort = 1210) (Additional file 2; 
Tables S5, S6, S7 and S8). The control cohort (N = 288) was employed to set up and to estimate the parameters 
needed by  TADA18 (Additional file 1; Table S4).
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Two classes of DNMs were included in the analysis: LoF and probably damaging missense mutations. To 
set up mutational rates for each mutational category, we used the per gene mutation rates table data computed 
by Samocha et al.23 and then, the following formula was applied to calibrate them: LoF; (nonsense + splice) x 
 (synobs/synexp) and probably damaging missense; missense ×  (NProb.damaging /Nallmissense) x  (synobs/synexp).  Synobs 
is the observed number of synonymous mutations in the control cohort of unaffected siblings (N = 119)18, and 
 synexp is the expected number of synonymous DNMs in the same cohort calculated from the sum of per-gene 
synonymous DNMs rates (2*n*µ) (N = 79.04).  Nprob.damaging is the number of probably damaging missense muta-
tions in the control cohort (N = 212) and N allmissense were the total of missense mutations in the control cohort 
(N = 296). To estimate the relative risk (γ) for each mutational category, we calculated the burden (ƛ) of muta-
tions of each type in cases (Spanish cohort) over controls (LoF = 2.21; probably damaging missense = 1.36). 
Then we applied the following formula to calculate relative risk: ɣ = 1 + (ƛ − 1)/π, where π, the fraction of risk 
genes, was set as 0.05 (the default parameter). Finally, by running TADA-Denovo with the parameters described 
above, uncorrected p values for each gene were calculated obtaining null distributions (N repetitions = 10,000). 
TADA-Denovo computes BF (Bayesian Factor) to each gene. To determine an appropriate threshold that allows 
declaring a “significant gene”, TADA uses the Bayesian FDR approach to control for the rate of false discoveries. 
q-values for each gene were calculated using the Bayesian FDR approach provided by TADA. Manhattan plots 
which show the results of TADA p values (− log10) for the combined cohort (PZMs and germinal mutations) 
were done with R package  qqman24.
Genes with FDR < 0.1 (germinal genes) and FDR < 0.3 (PZMs genes) were classified according to SFARI 
criteria (https ://gene.sfari .org/datab ase/gene-scori ng/). Moreover, OMIM database (Online Mendelian Inherit-
ance in Man) (https ://www.omim.org/) was consulted to search for Mendelian diseases related to these genes.
Gene‑set enrichment analysis of PZMs and germinal mutations. Gene-set enrichment analyses of 
those genes carrying missense and nonsense DNMs (germinal and PZMs) was done by  DNENRICH25. DNEN-
RICH estimates the enrichment of DNMs within pre-defined groups of genes accounting for gene size, tri-
nucleotide context and functional effect of the mutations. DNMs included in this analysis were germinal and 
PZMs identified in the Spanish cohort (germinal DNMs = 236; PZMs = 164) (Additional file 3; Tables S9 and 
S10). For the analysis of the combined cohort, a subset of PZMs was created in order to ensure that the analyzed 
PZMs likely contribute to the phenotype (PZMs = 676) (Additional file 1; Table S11). For that purpose, individu-
als with germinal mutations in ASD risk genes (SFARI scores 1 and 2) were eliminated from the PZMs dataset. 
Thus, germinal DNMs and the subset of PZMs from the combined cohort were used in the analysis (germinal 
DNMs = 2270; PZMs = 676) (Additional file 3; Table S12 and S13). The analysis was also run independently in 
unaffected siblings using data previously published by the ASC (germinal DNMs = 780; PZMs = 239) (Additional 
file 1; Table S14).
The gene name alias and the gene size matrix provided by DNENRICH were used as input files used in this 
analysis together with the following gene-sets: (1) FMRP target genes identified by Darnell et al.26 and down-
loaded from Genebook (http://zzz.bwh.harva rd.edu/geneb ook/) (N = 788); (2) Genes included in the GO:0006325 
chromatin organization (N = 723) (http://www.geneo ntolo gy.org/); (3) Synaptic genes (N = 903)27; (4) Human 
orthologs of genes essential in mice (N = 2472)28; (5) CHD8 target genes in human mid fetal brain (N = 2725)29; 
(6) List of SFARI genes (N = 990) (https ://gene.sfari .org/autdb /HG_Home); (7) LoF intolerant genes (pLi > 0.9) 
(N = 3230)29,30; 8) RBFOX target genes (N = 587)31; (9) miR-137 target genes (N = 428)32; (10) CELF-4 target genes 
(N = 954)33; (11) Allele biased genes in differentiating neurons (N = 802)34; (12) Known intellectual disability 
genes (N = 1547)35; (13) Intergenic and Intronic Brain Expressed Enhancers (BEE) (N = 673)36; (14) Genomic 
intervals surrounding known telencephalon genes scanned for enhancers (N = 79)37; and (15) miR-138 target 
genes (N = 255)38. Empirical p values were obtained from one million permutations for each gene-set.
Gene ontology enrichment analysis. An exploratory GO enrichment analysis was carried out using the 
Enrichr tool. This analysis allows studying if genes harboring germinal DNMs or PZMs are involved in different 
biological processes. To this aim, the combined dataset of germinal missense and nonsense DNMs and the sub-
set of PZMs were employed (germinal genes = 1972; PZMs genes = 624) (Additional file 3; Table S15). In addi-
tion, the REViGO tool (http://revig o.irb.hr/) was employed to visualize GO terms in semantic similarity-based 
scatterplots using SimRel as a semantic similarity measure. Thus, the top 30 enriched GO terms in each group 
(PZM vs germinal) were visualized using a modification of the R script provided by the REViGO online tool.
Network visualization of the top 50 enriched terms in each group of genes was performed with Enrichment 
Map, a Cytoscape (v.3.6.1) plugin for functional enrichment  visualization39. Each node represents a gene-set 
(GO term) and the size of the node is proportional to the number of genes participating in the GO term (overlap 
coefficient). Nodes were considered as connected when the overlap coefficient was greater than 0.7 and edge-
width represents the overlap between gene-sets. The border-width of each node represents the corresponding 
p value for each GO term.
Expression cell‑type enrichment analysis and expression analysis across brain regions and 
developmental periods. Expression Weighted Cell-type Enrichment (EWCE) method (https ://githu 
b.com/Natha nSken e/EWCE) was used to explore whether genes harboring germinal DNMs (N = 1972) and 
genes harboring PZMs (N = 624) (Additional file 3; Table S15) were differentially expressed across several neu-
ronal cell types. EWCE involves testing whether the given genes in a target list have higher levels of expression in 
a given cell type compared to what is expected by chance. Brain single-cell transcriptomic data from Karolinska 
Institute (ctd_allKI) was used for the EWCE analysis. Brain regions included in the KI mouse super dataset 
are the neocortex, hippocampus, hypothalamus, striatum, and midbrain, as well as samples enriched for oli-
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godendrocytes, dopaminergic neurons and cortical parvalbumin interneurons (total cells = 9970). Background 
gene-set comprises all human-mice orthologous. Probability distribution for our gene lists was calculated by 
randomly sampling 100,000 genes from the background set controlling for transcript length and GC content. 
Bootstrapping function was then applied on level 1 annotation.
pSI (specificity index statistic), an R package, was employed to study the expression of genes harboring PZMs 
and germinal mutations across different brain regions and neurodevelopmental  periods40,41. Lists of specifically 
expressed human genes (human.rda) obtained from BrainSpan data (gene-sets for 6 brain regions and gene-
sets for 10 developmental periods) were employed. The Fisher iteration test included in the pSI package was 
used to analyze if the listed genes harboring PZMs and germinal mutations were significantly overrepresented. 
Brain areas significantly enriched with PZMs or germinal genes in specific developmental periods (p adjusted 
value < 0.05) were represented as a matrix. Biorender (https ://biore nder.com) was used to draw the brain images 
(Fig. 6).
Ethics approval and consent to participate. The corresponding Research Ethics Committee of Gali-
cia approved our study: (Comité Ético de Investigación Galicia (the only IEC authorized in this autonomous 
region); Number: 2012/098; Approval: 28-June-2012; Title: Contribución a la búsqueda de las causas genéticas 
de los trastornos del espectro autista. All participants, parents or legal representatives provided written informed 
consent at enrollment and the study was conducted according to the declaration of Helsinki. The ASC data 
employed in this study were already published (https ://doi.org/10.1038/nn.4598). The corresponding ethics 
committee has approved these genetic data.
Results
Transmission and de novo association test (TADA‑denovo). Transmission and De novo Associa-
tion test (TADA) assesses if a gene is affecting ASD risk based on several parameters: the gene mutation rate, 
the recurrence of DNMs in the gene and the severity of the  mutations22. Thus, TADA-Denovo analysis was 
independently run in both datasets (germinal and PZMs genes). The main aim of TADA-Denovo is to identify 
those genes that could be differentially involved in ASD etiology depending on the type of DNMs harbored by 
them (germinal or PZMs). We focused the analysis on damaging mutations (LoF and likely pathogenic missense 
variants) to increase the likelihood of finding “strong” candidate genes. First, the set of genes from the Spanish 
cohort (360 trios) (germinal genes = 181; PZMs genes = 105) was analyzed. The analysis of the germinal gene 
list identified 12 genes with an FDR < 0.3 (Table 1 and Additional file 2; Table S16) including 3 genes (SCN2A, 
ARID1B and CHD8) with an FDR < 0.1. The analysis of the PZMs gene list identified 13 genes with an FDR < 0.3 
(Table 1 and Additional file 2; Table S17) of which 4 genes (KMT2C, FRG1, GRIN2B and MAP2K3) had an 
FDR < 0.1.
In the combined cohort (genes from the Spanish cohort plus genes from the Lim et al.  publication18 (germinal 
genes = 1210; PZMs genes = 362) TADA identified 34 genes with an FDR < 0.1 (Table 2 and Fig. 1a) and 103 genes 
with an FDR < 0.3 (Additional file 2; Table S18). Three of the genes (SCN2A, ARID1B, CHD8) with germinal 
DNMs were prioritized (FDR < 0.1) both in the combined cohort and in the Spanish cohort when TADA was 
employed. Analysis of PZMs genes in the combined cohort identified three genes (FRG1, KMT2C and NFIA) 
with an FDR < 0.1, and 14 genes with an FDR < 0.3 (Table 2 and Fig. 1b; Additional file 2; Table S19). Only two 
genes, KMT2C and FRG1, have remained significant after FDR correction (< 0.1) in both the Spanish and the 
combined cohort.
A total of 17 genes (50%) from the set of germinal genes in the combined cohort (34 genes, FDR < 0.1) were 
identified as “high confidence” or “strong” ASD candidates following SFARI Gene scoring criteria (scores 1, 
2, 1 s and 2 s). In addition, 11 of these genes (64, 70%) have shown an FDR < 0.1 in previous TADA  analysis6. 
Moreover, 10 of the remaining genes identified by TADA (FDR < 0.1) are included in SFARI gene lists (scores 
3, 4 and 5) and 5 of the genes identified by TADA were reported in relation with another disease (not ASD) by 
OMIM database (Additional file 4; Table S20).
PZM analysis has shown association of KMT2C (SFARI score s2) as well as other 3 genes FDR < 0.1). It is 
worth to note that NFIA has been previously reported as a plausible candidate gene in ASD (SFARI score 4) but 
this is the first time that FRG1 is reported in ASD. SMARCA4, PRKDC, KLF16, GRIN2B and HNRNPU (SFARI 
score 3 and 4) were among those plausible ASD candidate genes previously identified with an FDR value between 
0.1 and 0.3. GRIN2B was previously reported by SFARI as a strong ASD risk gene (score 1) (Additional file 4; 
Table S21).
Gene‑set enrichment analysis of PZMs and germinal mutations. DNENRICH was run to estimate 
a statistical significance of enrichment for germinal and PZMs within previously ASD and NDDs associated 
gene-sets. Synonymous mutations were excluded from the analysis because they are unlikely to contribute to 
ASD phenotype and only nonsense and missense mutations were considered. First, gene-set enrichment analysis 
was performed using the list of genes and DNMs (germinal and PZMs) from the Spanish cohort (Additional 
file 3; Tables S9 and S10) against several background gene lists (see “Methods” section). Our results indicate that 
germinal genes shown enrichment in several gene-sets (germinal genes = 228, germinal DNMs = 236): FMRP 
target genes (p value = 0.003), known intellectual disability genes (p value = 0.0073), LoF intolerant genes (p 
value = 0.002), SFARI genes (p value = 1 × 10–7) and genes involved in chromatin organization (p value = 0.00018) 
(Table 3). However, only the LoF intolerant gene-set has shown association with the list of PZMs genes (PZMs 
genes = 155, PZMs = 164) (Table 3).
DNENRICH analysis in the combined cohort demonstrated enrichment for several gene-sets for both ger-
minal and PZMs genes: chromatin organization, SFARI genes, LoF intolerant genes, CHD8 target genes and 
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essential genes. In addition, the germinal gene list (germinal genes = 1972, germinal DNMs = 2270) showed 
enrichment for FMRP target genes (p value = 1 × 10–6), known intellectual disability genes (p value = 1 × 10–6) and 
synaptic genes (p value = 4 × 10–6) (Table 4, Fig. 2). PZMs genes (PZMs genes = 624, PZMs = 676), have only shown 
association in the case of the miR-137 target gene-set (p value = 0.0019) (Table 4, Fig. 2). The same analysis was 
performed using the list of germinal genes from unaffected siblings (germinal genes = 744, germinal DNMs = 780; 
PZMs genes = 237, PZMs = 239) (Additional file 1; Table S14). A significant enrichment was identified only with 
the FMRP targets gene-set (data not shown).
Gene ontology enrichment analysis. GO enrichment analysis revealed remarkable differences between 
germinal and PZMs gene lists from the combined cohort (Additional file 3; Table S15). The germinal set showed 
a significant enrichment in different GO terms related to synaptic function and transcription regulation. In 
particular, it is worth to note the association of GO terms related to ion transport: GO:0006814, Benjamini-
Hochberg-corrected p[Pbh] = 0.005; GO0035725, Pbh = 0.005 and GO0006816, Pbh = 0.006 (Additional file 4; 
Table  S22, Fig.  3a). The GO terms enriched in the subset of PZMs are related to regulation of gene expres-
sion, biosynthesis, differentiation or migration: GO0010629, p[Pbh] = 0.074; GO:2000113, p[Pbh] = 0.092; 
GO:0045652, p[Pbh] = 0.092; GO:0030336, p[Pbh] = 0.0995. (Additional file 4; Table S23, Fig. 3b).
GO enrichment analysis was depicted by semantically clustering the top 50 enriched terms for germinal and 
PZMs gene lists. The germinal gene list resulted in three differentiated clusters: neuron development and dif-
ferentiation, synaptic functions, and chromatin modifications. The existence of a fourth cluster, which includes 
terms related to embryonic development, was also highlighted (Fig. 4a). In the case of PZMs genes, all the clusters 
were partially related to each other. However, we identified another cluster that includes terms related to the 
regulation of core processes (e.g., protein phosphorylation, regulation of growth, negative regulation of cellular 
biosynthetic processes, positive regulation of transcription DNA template). It is also important to highlight the 
GO terms related to neuron and embryonic development (Fig. 4b).
Expression cell‑type enrichment analysis and expression analysis across brain regions and 
developmental periods.. First, we examined whether germinal genes or PZMs genes from the combined 
cohort, were differentially expressed in the transcriptome dataset corresponding to level 1 cell types. As expected, 
germinal genes were significantly enriched in several cell types (Additional file 3; Table S24; Fig. 5). The most 
enriched cell types were those related to neurotransmission (dopaminergic neuroblast; p value < 0.0001; embry-
onic dopaminergic neurons, p value < 0.0001; embryonic GABAergic neurons, p value < 0.0001; serotonergic 
Table 1.  ASD risk genes carrying germinal DNMs and PZMs in the Spanish cohort. p values and q-values 
were obtained after running TADA-Denovo using germinal DNMs and PZMs from the Spanish ASD cohort 
(N = 360). Only genes with q-values < 0.3 are shown.
Genes q-value p value Mutations
SCN2A 0.004 2.76 × 10–7 Germinal
ARID1B 0.050 2.76 × 10–6 Germinal
CHD8 0.066 3.31 × 10–6 Germinal
FIG4 0.103 9.39 × 10–5 Germinal
RBM15 0.126 1.16 × 10–5 Germinal
HUWE1 0.148 3.54 × 10–5 Germinal
KIAA1107 0.188 5.08 × 10–5 Germinal
VWAS5B1 0.218 5.08 × 10–5 Germinal
EMCN 0.242 6.13 × 10–5 Germinal
SH2B2 0.262 7.90 × 10–5 Germinal
ASMT 0.277 9.34 × 10–5 Germinal
MYLK4 0.291 9.67 × 10–5 Germinal
KMT2C 0.001 4.76 × 10–7 PZM
FRG1 0.015 4.46 × 10–7 PZM
GRIN2B 0.040 4.76 × 10–7 PZM
MAP2K3 0.08 6.67 × 10–6 PZM
SRGAP2 0.106 7.62 × 10–6 PZM
MBD6 0.124 7.62 × 10–6 PZM
POTEB2 0.168 2.57 × 10–5 PZM
CALML6 0.200 2.67 × 10–5 PZM
PRDX6 0.226 3.05 × 10–5 PZM
SSR2 0.245 3.14 × 10–5 PZM
VEGFA 0.264 4 × 10–5 PZM
CANX 0.278 0.0001 PZM
ZNF276 0.290 0.00012 PZM
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Table 2.  ASD risk genes carrying germinal DNMs and PZMs in the combined cohort. p values and q-values 
were obtained after running TADA-Denovo using germinal DNMs and PZMs from the combined cohort 
(N = 2103). Genes with q-values < 0.1 are shown in the case of germinal DNMs and genes with q-value < 0.3 are 
shown in the case of PZMs.
Gene q-value p value Mutations
SCN2A 5.04 × 10–12 4.13 × 10–8 Germinal
CHD8 2.40 × 10–5 4.13 × 10–8 Germinal
ARID1B 5.36 × 10–5 4.13 × 10–8 Germinal
SLC6A1 0.00015 2.48 × 10–7 Germinal
SYNGAP1 0.0005 6.61 × 10–7 Germinal
KDM5B 0.0008 8.26 × 10–7 Germinal
SUV420H1 0.002 5.37 × 10–6 Germinal
TRIP12 0.003 5.79 × 10–6 Germinal
PTEN 0.004 1.14 × 10–5 Germinal
KATNAL2 0.008 5.01 × 10–5 Germinal
NRXN1 0.012 5.79 × 10–5 Germinal
CREBBP 0.02 5.92 × 10–5 Germinal
CELF4 0.02 6.09 × 10–5 Germinal
STXBP1 0.02 6.48 × 10–5 Germinal
DYRK1A 0.02 7.09 × 10–5 Germinal
CHD2 0.03 0.0001 Germinal
ANK2 0.03 0.0001 Germinal
WDFY3 0.03 0.0001 Germinal
UNC80 0.04 0.0002 Germinal
CLASP1 0.04 0.0002 Germinal
TMEM39B 0.05 0.0002 Germinal
PRKAR1B 0.05 0.0002 Germinal
USP45 0.05 0.0003 Germinal
NUAK1 0.06 0.0004 Germinal
NAA15 0.06 0.0004 Germinal
FOXP1 0.07 0.0004 Germinal
ZC3H11A 0.07 0.0004 Germinal
DPP3 0.07 0.0005 Germinal
PRKDC 0.08 0.0005 Germinal
ATP1A1 0.08 0.0005 Germinal
LRP5 0.09 0.0005 Germinal
SLC12A3 0.09 0.0006 Germinal
FBXO18 0.096 0.0006 Germinal
PTK7 0.0999 0.0007 Germinal
FRG1 0.04 4.14 × 10–3 PZM
KMT2C 0.07 0.00018 PZM
NFIA 0.09 0.00028 PZM
SMARCA4 0.12 0.00052 PZM
PRKDC 0.13 0.00055 PZM
KLF16 0.15 0.00064 PZM
GRIN2B 0.17 0.00095 PZM
MAP2K3 0.18 0.00098 PZM
HNRNPU 0.21 0.0019 PZM
POTEB2 0.23 0.002 PZM
RNPC3 0.25 0.002 PZM
FAM177A1 0.27 0.002 PZM
CALML6 0.28 0.002 PZM
CMPK2 0.3 0.003 PZM
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neurons, p value < 0.0001). The PZMs gene list showed enrichment for three different cell types: pyramidal CA1 
neurons; p value = 0.0066, pyramidal somatosensory (SS); p value = 0.0152, embryonic midbrain nucleus neu-
rons; p value = 0.0185 (Additional file 3; Table S25, Fig. 5).
To gain insight into the spatiotemporal distribution, we analyzed the expression of germinal and PZMs genes 
(Additional file 3; Table S15) across several brain regions and different neurodevelopmental periods obtained 
Figure 1.  Manhattan plots depicting the ASD risk genes prioritized by TADA-Denovo (chromosome and 
log10 p value for each gene are represented in axis x and y). (a) p values were obtained from analysis of germinal 
mutations in the combined cohort using TADA-Denovo. Red line represents the p value < 1 × 10–8 and blue line p 
value < 1 × 10−5. (b) p values were obtained from analysis of PZMs in the combined cohort using TADA-Denovo. 
Blue line represents p value < 1 × 10−5.
Table 3.  Results of the gene-set enrichment analysis for the list of genes harboring germinal DNMs and PZMs 
(Spanish cohort).
Gene-sets p value Observed mutations Expected mutations Analysis
SFARI genes 1 × 10–6 49 20.9601 Germinal
FMRP targets 0.00013 39 20.9788 Germinal
Genes involved in chromatin organization 0.00018 24 10.7377 Germinal
LoF intolerant genes 0.0018 79 58.9156 Germinal
Known ID genes 0.0073 40 27.0286 Germinal
Essential genes 0.0709 49 39.968 Germinal
CHD8 targets 0.226 39 34.4983 Germinal
mir137 targets 0.3251 8 6.49354 Germinal
Synaptic genes 0.3592 14 12.4002 Germinal
Genomic intervals surrounding known telencephalon genes 
scanned for enhancers 0.5386 1 0.771873 Germinal
Alelle biased genes in differentiating neurons 0.6 12 12.502 Germinal
CELF4 targets 1 0 0.05078 Germinal
mir128 targets 1 0 0.022676 Germinal
RBFOX targets 1 0 0.055409 Germinal
LoF intolerant genes 0.0283 51 39.9973 PZM
Genes involved in chromatin organization 0.0625 12 7.28793 PZM
FMRP targets 0.0764 20 14.2422 PZM
Sfari genes 0.0764 20 14.2361 PZM
CHD8 targets 0.0884 30 23.4115 PZM
Genomic intervals surrounding known telencephalon genes 
scanned for enhancers 0.0977 2 0.524631 PZM
Essential genes 0.234 31 27.1352 PZM
Synaptic genes 0.3339 10 8.41702 PZM
Known ID genes 0.7554 16 18.3456 PZM
mir137 targets 0.8198 3 4.40692 PZM
Alelle biased genes in differentiating neurons 0.9727 4 8.48746 PZM
CELF4 targets 1 0 0.034487 PZM
mir128 targets 1 0 0.015316 PZM
RBFOX targets 1 0 0.037786 PZM
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from BrainSpan. Germinal genes were significantly expressed in the cortex, striatum, cerebellum and amygdala 
in prenatal stages (early, early mid and late) (Additional file 3; Table S26, Fig. 6a,c). PZMs genes were significantly 
expressed in the cortex during the early mid-fetal period. Although we did not find found a significant enrich-
ment in other brain areas or neurodevelopmental periods for PZMs, p values close to the significance threshold 
were found in cortex (early, late mid-fetal) and amygdala (late mid-fetal) (Additional file 3; Table S27, Fig. 6b,d).
Table 4.  Results of the gene-set enrichment analysis for the list of genes harboring germinal DNMs and PZMs 
(combined cohort).
Gene-set p value Observed mutations Expected mutations Analysis
Essential genes 1 × 10–6 533 404.162 Germinal
FMRP targets 1 × 10–6 331 212.218 Germinal
Known ID genes 1 × 10–6 373 273.213 Germinal
LoF intolerant genes 1 × 10–6 733 595.59 Germinal
SFARI genes 1 × 10–6 434 211.973 Germinal
Synaptic genes 4 × 10–6 180 125.408 Germinal
Genes involved in chromatin organization 1 × 10–6 168 108.449 Germinal
CHD8 targets 3.5 × 10–5 420 348.544 Germinal
Genomic intervals surrounding known telencephalon genes 
scanned for enhancers 0.0550 13 782.029 Germinal
mir137 targets 0.1368 75 657.234 Germinal
RBFOX targets 0.4299 1 0.562709 Germinal
Alelle biased genes in differentiating neurons 0.6999 121 126.324 Germinal
CELF4 targets 1 0 0.51357 Germinal
mir128 targets 1 0 0.22838 Germinal
SFARI genes 1 × 10–7 127 612.987 PZM
LoF intolerant genes 0.0003 212 172.214 PZM
mir137 targets 0.0019 33 190.234 PZM
Genes involved in chromatin organization 0.0106 45 313.424 PZM
Essential genes 0.0118 140 116.895 PZM
CHD8 targets 0.0228 120 100.751 PZM
FMRP targets 0.0425 75 614.294 PZM
Genomic intervals surrounding known telencephalon genes 
scanned for enhancers 0.0796 5 22.672 PZM
Known ID genes 0.1840 87 790.127 PZM
Synaptic genes 0.6109 35 362.813 PZM
Alelle biased genes in differentiating neurons 0.9744 26 364.938 PZM
CELF4 targets 1 0 0.147914 PZM
mir128 targets 1 0 0.066195 PZM
RBFOX targets 1 0 0.162842 PZM
Figure 2.  Gene-set enrichment analysis using germinal and PZM from the combined cohort. Gene-set 
enrichment analysis was done with DNENRICH. − log10 p value for each gene-set is shown for each type of 
mutation and tested gene-set.
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Discussion
ASD is a complex NDD, characterized by its clinical and genetic heterogeneity. It is estimated that over 1000 genes 
are involved in causing ASD but it is difficult to track them down and to functionally characterize them. Thus, 
it is widely believed that the vast majority of ASD genetic factors remain largely  unknown6. In addition, DNMs 
are a strong source of genetic causality in ASD even though they have been usually identified in a germinal state. 
This means that most of the ASD genetic studies do not consider DNMs that appear post-zygotically. Recent 
studies have suggested that some ASD candidate genes could carry more mosaic mutations than  others15–18. 
However, the phenotypic effect of PZMs and its impact in clinical diagnosis is not completely understood. A 
recent study showed that brain malformations can occur when around 10% of peripheral blood cells harbor the 
mosaic  mutation42. In addition, mosaic mutations could act as phenotype modifiers, resulting in patients who 
have less severe  symptoms43.
This study has explored the possibility of finding new genetic risk factors in ASD when PZMs are also con-
sidered as well as it was focused on the deepening of their biological role. Three genes were associated in the 
PZM analysis done by TADA (q-value < 0.1; FRG1, KMT2C and NFIA) in the combined cohort. FRG1 has not 
been previously associated with NDDs while both, KMT2C and NFIA, have been previously reported as possible 
implicated in ASD and intellectual  disability44,45. However, none of these genes were associated to ASD in the 
germinal analysis, which seems to point that they tend to differentially harbor PZMs.
Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) (also other aliases) encodes a cyto-
plasmic protein involved in muscular and vascular development. FRG1 mapped 100 kb centromeric of the 
repeated units on chromosome 4q35 that contribute to the development of Facioscapulohumeral Muscular 
Dystrophy (FSHD, OMIM #158900)46. Although the molecular pathogenesis of FSHD remains unveiled, it is a 
muscular disease that shows comorbidity with several neurological symptoms such as epilepsy or intellectual 
 disability47. FRG1 can act as a splicing regulator and regulates the expression of Rbfox1, an RNA-binding protein 
that it is involved in neuronal migration and synapse formation. Mutations in RBFOX1 have been associated with 
 ASD48,49. Our study reveals the association of FRG1 in ASD when PZMs are considered. FRG1 association was 
not reported in the previous Lim et al. publication because it can be explained by novel nonsense PZM found in 
the Spanish cohort (Additional File 1, Table S1). However, this association should be interpreted with caution 
because FRG1 is not constraint for truncating (pLI = 0) or for missense variants (Z = 0.18).
KMT2C (lysine (K)-specific methyltransferase 2C) encodes a methyltransferase that regulates gene transcrip-
tion. De novo LoF mutations in KMT2C have been detected in individuals with Kleefstra syndrome 2 (OMIM 
#617768). Kleefstra syndrome is caused by haploinsufficiency of the euchromatin histone methyltransferase 1 
(EHMT1) and characterized by ASD and other comorbid symptomatology as intellectual disability and a delayed 
psychomotor development. These symptoms could be explained by a molecular interplay between KMT2C and 
EHMT1 both involved in the regulation of synaptic plasticity in the adult  brain44. WES focused on the detec-
tion of PZMs using new bioinformatic pipelines have found mosaic mutations within KMT2C15. These previous 
findings and the association of KMT2C in our study seem to point that some genes previously identified as 
high-confidence ASD risk genes can also harbor PZMs.
The third gene associated in the PZM analysis is NFIA (Nuclear Factor I A). It encodes a member of the 
NF1 (nuclear factor 1) family of transcription factors determining the regulation of gliogenesis and other neu-
ronal  processes50. Although two DNMs in NFIA have been previously reported in patients with intellectual 
disability, there is no reliable evidence to consider this gene as a high-confidence ASD risk  gene51. However, it 
is worth noting that an NFIA-related disorder caused by inherited or DNMs has been reported. This syndrome 
Figure 3.  Scatterplots representing the top 30 significant biological processes (combined cohort). (a) Top 30 
biological processes enriched in genes harboring germinal DNM are shown. (b) Top 30 biological processes 
enriched in genes harboring PZMs DNMs are shown.
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Figure 4.  Visualization of the top 50 GO terms grouped by clusters of biological functions (DNMs obtained 
from the combined cohort) (a) GO terms clusters for genes harboring germinal mutations. (b) GO terms 
clusters for genes harboring PZMs.
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is characterized by brain malformations and it is usually accompanied by renal urinary tract defects (OMIM 
#613735)52. The clinical presentation of the syndrome is highly variable and rarely all the described features are 
present in one  individual53. To our knowledge, this is the first time that NFIA is pointed as a plausible candidate 
gene in ASD. This association would have been dismissed without the analysis of PZMs.
The fact that different genes across the genome carry different types of DNMs (germinal and/or PZM), could 
be due to the fact that some mutations can be lethal in a germinal state but not in a mosaic state. This is the case, 
for example, of Rett syndrome, in which MECP2 mutations are lethal in males and dominant in females, but in 
a few cases, mosaic mutations have been reported to be compatible with male  viability54. However, our results, 
interpreted in conjunction with previous genetic and phenotypic studies, seem to point to other reasonable 
hypothesis: clinical manifestations caused by PZMs are usually less severe than those due to germinal mutations. 
Figure 5.  Expression Weighted Cell type Enrichment for PZM and germinal genes.
Figure 6.  Expression analysis across developmental stages and brain areas for germinal and PZMs genes from 
the combined cohort. Expression gene sets were obtained from BrainSpan. (a,c) Expression of germinal genes 
across different brain regions and developmental periods. (b,d) Expression of PZMs genes across different brain 
regions and developmental periods.
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For instance, Kleefstra syndrome is caused by germinal LoF DNMs in KMT2C but, neverthless, PZMs cause a 
milder phenotype  presentation55. Thus, patients with less severe phenotypes and core ASD features are over-
represented in our cohort, allowing the detection of KMT2C association in the PZM analysis done with TADA, 
while patients carrying germinal DNMs in the same gene might have been excluded for presenting a syndromic 
form. For the same reason, NFIA could appear associated with ASD only when the mutations are mosaic.
From the biological point of view, the gene-set enrichment analysis done with both lists of genes harboring 
PZMs and germinal mutations both in the Spanish and in the combined cohort showed a significant enrich-
ment for several gene-sets previously involved in ASD pathogenesis: FMRP targets, genes involved in chromatin 
organization and high-confidence genes from  SFARI6. Curiously, only the gene-set enrichment analysis for genes 
harboring PZMs (combined cohort) showed a significant enrichment for miR-137 targets. The fact that this 
association was found in the combined cohort and not in the Spanish cohort could be mainly due to the inclusion 
of a greater number of PZMs and a subsequent increase of the statistical power. miR-137 is a non-coding RNA 
with a critical role during brain  development56. The expression of miR-137 is crucial to maintain the processes 
of neuronal differentiation and proliferation so it is involved in neuronal maturation, dendrite development 
and  synaptogenesis57–59. In addition, common genetic variants within the gene that encodes miR-137 have been 
associated with ASD and  schizophrenia60,61. In fact, the complete loss of miR-137 in mice is lethal, but a partial 
loss results in a phenotype that reproduces some of the core symptoms of ASD, such as repetitive behavior and 
impaired social  functions62.
The GO enrichment analysis also points out to different biological functions for those genes harboring 
germinal DNMs and  PZMs18,63 .Thus, GO terms mainly related to ion transport and modulation of the synaptic 
function were highlighted in germinal genes. However, PZMs genes were enriched in GO terms mainly related 
to the negative regulation of gene expression. The involvement of PZMs in gene regulation processes and not 
in fundamental biological processes such as synaptic transmission also supports the hypothesis that PZMs can 
cause milder clinical manifestations.
In order to provide a novel insight of the biological role of germinal DNMs versus PZMs in other biological 
hierarchies, two types of analysis have been carried out: a cell-type enrichment analysis and an spatio-temporal 
expression analysis across neurodevelopmental periods and brain areas. Germinal genes have shown a significant 
enrichment in both excitatory and inhibitory neurons while PZMs genes were mainly expressed in pyramidal 
neurons. In addition, it is worth to note that genes with germinal DNMs were expressed in both fetal and adult 
neurons across several brain areas (cortex, striatum, cerebellum and amygdala). However, the expression of genes 
carrying PZMs was restricted to the mid-fetal cortex. Interestingly, the study performed by Lim et al. highlighted 
the amygdala as the main brain area in which PZMs were enriched for expression. It should be considered that 
Lims study only includes PZMs within critical exons, in comparison with the current study that includes all 
genes carrying non-synonymous  PZMs18 .
An overall view of our results suggests the existence of distinct biological mechanisms caused by PZMs and 
germinal genes that could influence ASD susceptibility in different manners. Thus, impaired neuronal com-
munication linked to mutations in germinal genes support the theory that excitatory/inhibitory imbalance 
contributes to  ASD21,64. The fact that several brain areas are similarly affected during development might explain 
the clinical heterogeneity in ASD and the high comorbidity with other disorders such as epilepsy or intellectual 
disability in the presence of germinal variants. By contrast, although a replication in larger cohorts is needed, 
it has been suggested that individuals harboring PZMs might be less affected in terms of cognitive abilities. In 
these patients, some biological processes such as neurogenesis, neuronal migration and differentiation that occur 
within early developmental stages might be disrupted. However, this would only take place in some brain cells 
while the remaining cells will maintain a normal functioning. In agreement with this hypothesis, it was found 
that brains of children with ASD have shown patches of abnormal laminar organization that could be the result 
of an altered migration of a small fraction of  cells65.
Our results point out to a critical neurodevelopmental period during mid-fetal development in which the 
disruption of neurodevelopmental processes will take place. We demonstrated that ASD associated genes were 
expressed more often between mid-to-late fetal periods. In addition, although some genes harbor mutations in 
a mosaic state it is possible that the disruption of certain genes expressed during this crucial period would be 
enough to the later manifestation of ASD core symptoms.
Conclusions
In conclusion, this study provides an additional insight into the role of PZMs in ASD etiology. It supports previ-
ous evidence of a pathogenic role for PZMs and their contribution to ASD risk. Moreover, our results suggest that 
PZMs could be involved in different biological processes and neurodevelopmental stages that germinal mutations. 
It has been revealed that ASD risk genes can differentially harbor germinal and PZMs, which highlights the clini-
cal importance of the detection of both types of mutations. In addition, the integration of the genetic information 
(germinal and PZM) together with the phenotypical characterization could be also helpful in clinical practice.
Data availability
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